Effect of Low-Dose Statins in Addition to Standard Therapy on Brain Perfusion and Neurocognitive Performance in Patients with Major Depressive Disorder
- 28 January 2022
- journal article
- research article
- Published by S. Karger AG in Neuropsychobiology
- Vol. 81 (4) , 271-285
Abstract
Introduction: Major depressive disorder (MDD) is a prevalent condition which has a well-known association with ischemic cardiomyopathy, probably explained by an inflammatory mediator mechanism. Statins, besides reducing cholesterol production, have pleiotropic effects including anti-inflammatory activity. The goal was to evaluate the effect of statins as an addition to standard therapy on mood status, brain perfusion, and neurocognitive performance in MDD. Methods: We studied 20 MDD patients with brain single-photon emission tomography and Cambridge Neuropsychological Test Automated Battery (CANTAB), half randomized to 10 mg of Rosuvastatin or placebo, in addition to selective serotonin reuptake inhibitors (SSRIs) therapy and being reevaluated 3 months later. The images were compared using Statistical Parametric Mapping; clinical scores (Hamilton Depression Score with 17 items and Beck’s Depression Inventory) as well as neurocognitive parameters were applied as covariances (CoV) to estimate regional cerebral blood flow (rCBF) changes with both therapies. Results: Clinical scores decreased in both groups (p = 0.0001); Beck’s presented a larger decrease with statins. We observed significantly rCBF changes expressed as significant larger clusters of voxels (p < 0.05) in the pre/subgenual anterior cingulate plus orbitofrontal cortex and a small area in the posterior cingulate gyrus in the statins group, whereas it was not observed with placebo, when using clinical scores as CoV. A similar pattern of rCBF changes was present with emotions recognition, attentional, paired associates learning, spatial planning, and working memory tasks. Conclusion: Short-term use of low-dose statins in MDD patients under SSRIs results in important rCBF changes in key mood associated areas to improvement in neurocognitive performance. These findings, even though demonstrated in a small sample, could open a new therapeutic tool in the comprehensive management of this disorder.Keywords
This publication has 48 references indexed in Scilit:
- Cognitive impairment in euthymic major depressive disorder: a meta-analysisPsychological Medicine, 2012
- Decreased cerebral blood flow in the limbic and prefrontal cortex using SPECT imaging in a cohort of completed suicidesTranslational Psychiatry, 2011
- Toward an Anti-Inflammatory Strategy for DepressionFrontiers in Behavioral Neuroscience, 2011
- 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Correlation between cerebral blood flow and items of the Hamilton Rating Scale for Depression in antidepressant-naive patientsJournal of Affective Disorders, 2004
- Neurovascular regulation in the normal brain and in Alzheimer's diseaseNature Reviews Neuroscience, 2004
- Treatment of mood disordersNature Neuroscience, 2002
- A Review of the Pharmacologic and Pharmacokinetic Aspects of RosuvastatinThe Journal of Clinical Pharmacology, 2002
- Neurobiology of DepressionNeuron, 2002
- Platelet Function and SertralineAmerican Journal of Psychiatry, 2001